PTC Therapeutics (PTCT) CLO sells 5,894 shares after option exercise

Rhea-AI Filing Summary

PTC Therapeutics executive Mark Elliott Boulding reported option exercises and share sales. On February 17, 2026, he exercised stock options for 2,813 shares of common stock at $25.69 per share, increasing his direct common stock holdings to 114,125 shares.

On February 17–18, 2026, he sold a total of 5,894 shares of common stock in open-market transactions at prices around $69.29–$70.13 per share, pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on December 4, 2024. A portion of the shares sold was automatically sold to cover tax withholding obligations related to vesting restricted stock units. After these transactions, he directly owned 108,231 shares of common stock and 22,501 stock options that are currently exercisable.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Boulding Mark Elliott

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NJ 07059

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EXEC. VP AND CLO

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		M(1)		2,813	A	$25.69	114,125	D
Common Stock	02/17/2026		S(1)		2,811	D	$69.29(2)	111,314	D
Common Stock	02/17/2026		S(1)		2	D	$70.13	111,312	D
Common Stock	02/18/2026		S		3,081(3)	D	$69.36	108,231	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$25.69	02/17/2026		M(1)			2,813	(4)	02/14/2034	Common Stock	2,813	$0	22,501	D

Explanation of Responses:

1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024.

2. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $68.84 to $69.80 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

3. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,500 RSUs from a February 15, 2024 grant of 18,000 RSUs and the vesting of 1,600 RSUs from a February 15, 2024 grant of 3,200 RSUs.

4. Currently exercisable.

	/s/ Avraham S. Adler, Attorney-in-Fact	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did PTCT executive Mark Elliott Boulding report?

Mark Elliott Boulding reported exercising stock options and selling common shares. He exercised options for 2,813 shares, then sold a total of 5,894 common shares in open-market transactions, some of which were automatically sold to cover tax withholding on vested RSUs.

How many PTC Therapeutics (PTCT) shares did the executive sell and at what prices?

He sold 5,894 shares of PTC Therapeutics common stock. These open-market sales occurred at weighted average prices ranging from about $68.84 to $70.13 per share, according to the filing’s pricing footnote describing multiple trade executions within that range.

Were the PTCT insider share sales under a Rule 10b5-1 trading plan?

Yes, the filing states the sales were effected under a written Rule 10b5-1 trading plan. That plan was adopted on December 4, 2024, allowing pre-scheduled transactions, which can help separate trading decisions from day-to-day possession of potentially material nonpublic information.

Did the PTCT executive’s transactions include option exercises?

Yes, he exercised a stock option covering 2,813 shares of PTC Therapeutics common stock. The exercise is reported as a derivative transaction, with the corresponding issuance of 2,813 common shares, and the option position remaining at 22,501 currently exercisable options after the transaction.

Why were some PTC Therapeutics shares sold to cover taxes for the insider?

The filing explains that certain shares were automatically sold under an irrevocable sell-to-cover election. These sales satisfied tax withholding obligations arising from the vesting of restricted stock units granted on February 15, 2024, when 4,500 and 1,600 RSUs from prior grants vested.

How many PTC Therapeutics shares does the executive hold after these transactions?

After the reported transactions, Mark Elliott Boulding directly held 108,231 shares of PTC Therapeutics common stock. He also held 22,501 stock options that are currently exercisable, reflecting his remaining direct derivative interest in the company’s equity following the reported activity.